Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics

Area of Science:

• Pediatric Hematology
• Pharmacokinetics and Pharmacodynamics
• Hematopoietic Stem Cell Transplantation (HSCT)

Background:

• Age-related differences in drug metabolism impact HSCT outcomes in children.
• Current dosing strategies for HSCT conditioning and immunosuppression may not be optimal for pediatric patients.
• Personalized dosing aims to reduce graft rejection, relapse, and toxicity in pediatric HSCT recipients.

Purpose of the Study:

• To summarize pharmacokinetic/dynamic (PK/PD) data for HSCT conditioning and post-grafting immunosuppression in pediatric recipients.
• To highlight the need for personalized drug dosing in pediatric HSCT.
• To identify gaps in current PK/PD knowledge for key HSCT drugs in children.

Main Methods:

• Review of pharmacokinetic/dynamic data presented at the First Annual Pediatric Bone Marrow Transplant Consortium (PBMTC) meeting.
• Analysis of existing data on busulfan (BU) dosing and its achievement of target plasma exposure in children.
• Identification of limited PK data for other conditioning agents and evolving monitoring parameters for immunosuppressants like mycophenolic acid (MPA).

Main Results:

• Personalized busulfan (BU) dosing to a target plasma exposure reduces graft rejection in children and improves relapse/toxicity rates in adults.
• Current weight-based BU dosing achieves target exposure in only 24.3% of pediatric patients.
• Limited PK data exist for treosulfan, cyclophosphamide (CY), fludarabine, and alemtuzumab in pediatric HSCT conditioning.
• Mycophenolic acid (MPA) clearance may be higher in younger children (<12 years), with evolving monitoring parameters.

Conclusions:

• Personalized busulfan (BU) dosing is essential for improving outcomes in pediatric hematopoietic stem cell transplantation (HSCT).
• Current dosing regimens for BU and other conditioning agents require optimization based on PK/PD data.
• Further multi-institutional trials are needed to establish optimal PK/PD-guided dosing strategies for pediatric HSCT recipients.